# Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

> **NCT06771596** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 43 (actual)

## Conditions studied

- Uterine Cervical Neoplasms

## Interventions

- **DRUG:** Nimotuzumab Injection

## Key facts

- **NCT ID:** NCT06771596
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-12
- **Primary completion:** 2025-07
- **Final completion:** 2025-09
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06771596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06771596, "Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06771596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*